This article is
- freely available
Development of MicroRNA Therapeutics for Hepatocellular Carcinoma
Department of Radiology, University of Minnesota Medical School, MMC 292 Mayo Memorial Building, 420 Delaware Street S.E., Minneapolis, MN 55455, USA
Received: 5 February 2013; in revised form: 1 March 2013 / Accepted: 11 March 2013 / Published: 15 March 2013
Abstract: Hepatocellular carcinoma (HCC) is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. Treatment options for HCC are very limited, as it is often diagnosed at a late stage. Recent studies have demonstrated that microRNAs (miRNAs), a class of non-coding RNAs, are aberrantly expressed in HCC. Some of these were shown to be functionally involved in carcinogenesis and tumor progression, suggesting that miRNAs can serve as novel molecular targets for HCC therapy. Several promising studies have recently demonstrated the therapeutic potential of miRNAs in animal models and in reducing the viral load in hepatitis C patients. In this review, these advances and strategies for modulating miRNAs for in vivo therapeutic delivery and replacement therapy are discussed.
Keywords: microRNA; replacement therapy; liver cancer; animal model
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Aravalli, R.N. Development of MicroRNA Therapeutics for Hepatocellular Carcinoma. Diagnostics 2013, 3, 170-191.
Aravalli RN. Development of MicroRNA Therapeutics for Hepatocellular Carcinoma. Diagnostics. 2013; 3(1):170-191.
Aravalli, Rajagopal N. 2013. "Development of MicroRNA Therapeutics for Hepatocellular Carcinoma." Diagnostics 3, no. 1: 170-191.